翰宇药业股价下跌2.17% 与三生蔓迪签署减重药物商业化协议

Group 1 - The stock price of Hanyu Pharmaceutical on August 19 was 29.26 yuan, down 0.65 yuan or 2.17% from the previous trading day [1] - The opening price on that day was 29.83 yuan, with a highest point of 30.67 yuan and a lowest point of 28.58 yuan, with a trading volume of 1.5702 million hands and a transaction amount of 4.636 billion yuan [1] - Hanyu Pharmaceutical operates in the chemical pharmaceutical industry, focusing on the research and production of peptide drugs [1] Group 2 - On August 19, Hanyu Pharmaceutical signed a "Contract Manufacturing and Supply Agreement for Semaglutide Injection" with Zhejiang Sanofi Mandi Pharmaceutical, marking the commercial implementation of their collaboration in weight loss treatment [1] - The drug has completed the enrollment of all subjects in Phase III clinical trials and is currently in the stable dosing phase at the highest dose of 2.4 mg [1] Group 3 - On August 19, the net outflow of main funds was 336 million yuan, accounting for 1.63% of the circulating market value [1] - Over the past five trading days, the cumulative net outflow was 342 million yuan, representing 1.66% of the circulating market value [1]